Implementation of regenerative medicine in society and management support for medical institutions
First written in FY2025-H1. 9 of 13 entries say "Advanced", first in 2026-03-17. Latest entry: 2026-09-08.
1 other company's latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Revenue from support services for medical institutions amounted to ¥108.295 million, up 72.7% year on year.」
Regarding the social implementation of the regenerative medicine business and support for medical institutions, interim revenue from support services for medical institutions increased 72.7% year on year to ¥108.295 million. - FY2025RestatedAnnual report
「Based on the basic strategy described under Management Strategy 1, our subsidiary ハイブリッドメディカル株式会社 operates a business specialising in operational support for medical institutions to build closer relationships with medical institutions nationwide, primarily in orthopaedics.」
Through ハイブリッドメディカル株式会社, the structure for strengthening collaboration with and providing operational support to medical institutions nationwide, primarily in orthopaedics, continues to serve a strategic role. - FY2025-H1First statedAnnual report
「In November 2024, we established ハイブリッドメディカル株式会社 as a wholly owned subsidiary and included it in our consolidated results. To bring the regenerative medicine business into wider social use, the company is building closer relationships with medical institutions nationwide, primarily in orthopaedics, and is developing management support services for medical institutions.」
We established and consolidated ハイブリッドメディカル株式会社 as a wholly owned subsidiary, and began bringing regenerative medicine into wider social use by strengthening collaboration with medical institutions nationwide and providing management support services to them.